Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
BACKGROUND We present here the case of a patient with pulmonary arterial hypertension and NYHA Class II symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between these PAH medications. CASE PRESENTATION A 59-year old male with a history of anorexigen use initially presented in 2008 and was felt to have non-operable small vessel disease. His care was transitioned to our center after insurance would not cover high-dose sildenafil in addition to ERA therapy. CONCLUSION This case demonstrates a safe and successful transition from higher dose PDE-5is to riociguat with no interruption in therapy.